Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.
نویسندگان
چکیده
The risk for inhibitor development in mild hemophilia A (factor VIII levels between 5 and 40 U/dL) is larger than previously anticipated, continues throughout life, and is particularly associated with certain mutations in F8. Desmopressin may reduce inhibitor risk by avoiding exposure to FVIII concentrates, but the heterogenous biological response to desmopressin, showing large interindividual variation, may limit its clinical use. However, predictors of desmopressin response have been recently identified, allowing the selection of the best candidates to this treatment.
منابع مشابه
Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors
Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...
متن کاملFrequency of Decreased Bone Mineral Density and Its Risk Factors during Childhood among Iranian Hemophilia Patients
This study was undertaken to assess the frequency of decreased bone mineral density and its risk factors as well as its impact on the quality of life during childhood among hemophiliac patients. Materials and Methods: Thirty seven children with severe hemophilia A and B, referred to Mofid Children’s Hospital during 2010, were selected. For all patients the joint score, body mass indexes, bone...
متن کاملبررسی پلی‌مورفیسم ژن های IGSF2 و TNFα و خطر توسعه مهار کننده در بیماران مبتلا به هموفیلی A
Background and purpose: Hemophilia is a hereditary X-linked disorder. Females are carriers and males have the disorder. Hemophilia A is caused by deficiency in the production of factor VIII. In some hemophilia patients, inhibitors including IgG1 and IgG4 antibodies are expressed against this factor. These inhibitors interact with factor VIII and suppress its function. The current study aimed at...
متن کاملThe Survey of Effective Agents on Factor VIII and IX Inhibitors in Patients with Hemophilia A and B in Kermanshah Province
Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this population and its associated factors. Methods: This study was conducted on patients with hemophilia...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 124 15 شماره
صفحات -
تاریخ انتشار 2014